The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.
This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP.
Funding is open to researchers and clinicians worldwide at:
- Academic medical centers and universities or nonprofits. Industry partnerships are strongly encouraged.
- Biotechnology companies. Existing companies and new startups are both eligible.
- NOTE: Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones (see Our Research Strategy for more information).
Letter of Intent:
February 4, 2022
May 20, 2022
September 30, 2022
April 8, 2022
July 22, 2022
December 2, 2022